Tang Zhen-Ming, Ling Zhou-Gui, Wang Chun-Mei, Wu Yan-Bin, Kong Jin-Liang
Department of Respiratory Medicine, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China.
Department of Respiratory Medicine, the People's Hospital of Shenzhen Guangming New District, Shenzhen, China.
PLoS One. 2017 Jul 27;12(7):e0182117. doi: 10.1371/journal.pone.0182117. eCollection 2017.
We performed a comprehensive review and meta-analysis to evaluate the diagnostic values of serum single and multiplex tumor-associated autoantibodies (TAAbs) in patients with lung cancer (LC).
We searched the MEDLINE and EMBASE databases for relevant studies investigating serum TAAbs for the diagnosis of LC. The primary outcomes included sensitivity, specificity and accuracy of the test.
The systematic review and meta-analysis included 31 articles with single autoantibody and 39 with multiplex autoantibodies. Enzyme-linked immunosorbent assay (ELISA) was the most common detection method. For the diagnosis of patients with all stages and early-stage LC, different single or combinations of TAAbs demonstrated different diagnostic values. Although individual TAAbs showed low diagnostic sensitivity, the combination of multiplex autoantibodies offered relatively high sensitivity. For the meta-analysis of a same panel of autoantibodies in patients at all stages of LC, the pooled results of the panel of 6 TAAbs (p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1 and SOX2) were: sensitivity 38% (95% CI 0.35-0.40), specificity 89% (95% CI 0.86-0.91), diagnostic accuracy 65.9% (range 62.5-81.8%), AUC 0.52 (0.48-0.57), while the summary estimates of 7 TAAbs (p53, CAGE, NY-ESO-1, GBU4-5, SOX2, MAGE A4 and Hu-D) were: sensitivity 47% (95% CI 0.34-0.60), specificity 90% (95% CI 0.89-0.92), diagnostic accuracy 78.4% (range 67.5-88.8%), AUC 0.90 (0.87-0.93). For the meta-analysis of the same panel of autoantibodies in patients at early-stage of LC, the sensitivities of both panels of 7 TAAbs and 6 TAAbs were 40% and 29.7%, while their specificities were 91% and 87%, respectively.
Serum single or combinations of multiplex autoantibodies can be used as a tool for the diagnosis of LC patients at all stages or early-stage, but the combination of multiplex autoantibodies shows a higher detection capacity; the diagnostic value of the panel of 7 TAAbs is higher than the panel of 6 TAAbs, which may be used as potential biomarkers for the early detection of LC.
我们进行了一项全面的综述和荟萃分析,以评估血清单一和多重肿瘤相关自身抗体(TAAbs)对肺癌(LC)患者的诊断价值。
我们在MEDLINE和EMBASE数据库中搜索了有关研究血清TAAbs用于诊断LC的相关研究。主要结果包括检测的敏感性、特异性和准确性。
系统综述和荟萃分析纳入了31篇关于单一自身抗体的文章和39篇关于多重自身抗体的文章。酶联免疫吸附测定(ELISA)是最常用的检测方法。对于所有阶段和早期LC患者的诊断,不同的单一TAAbs或其组合显示出不同的诊断价值。尽管单个TAAbs的诊断敏感性较低,但多重自身抗体的组合提供了相对较高的敏感性。对于LC各阶段患者同一组自身抗体的荟萃分析,6种TAAbs(p53、NY-ESO-1、CAGE、GBU4-5、膜联蛋白1和SOX2)组合的汇总结果为:敏感性38%(95%CI 0.35-0.40),特异性89%(95%CI 0.86-0.91),诊断准确性65.9%(范围62.5-81.8%),AUC 0.52(0.48-0.57),而7种TAAbs(p53、CAGE、NY-ESO-1、GBU4-5、SOX2、MAGE A4和Hu-D)组合的汇总估计值为:敏感性47%(95%CI 0.34-0.60),特异性90%(95%CI 0.89-0.92),诊断准确性78.4%(范围67.5-88.8%),AUC 0.90(0.87-0.93)。对于早期LC患者同一组自身抗体的荟萃分析,7种TAAbs和6种TAAbs组合的敏感性分别为40%和29.7%,而它们的特异性分别为91%和87%。
血清单一或多重自身抗体组合可作为诊断各阶段或早期LC患者的工具,但多重自身抗体组合显示出更高的检测能力;7种TAAbs组合的诊断价值高于6种TAAbs组合,其可能作为LC早期检测的潜在生物标志物。